Wall Street brokerages forecast that Horizon Pharma PLC (NASDAQ:HZNP) will announce earnings per share (EPS) of $0.22 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Horizon Pharma PLC’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.25. Horizon Pharma PLC posted earnings of $0.66 per share during the same quarter last year, which would indicate a negative year over year growth rate of 66.7%. The business is expected to report its next earnings results on Monday, February 26th.

According to Zacks, analysts expect that Horizon Pharma PLC will report full-year earnings of $1.10 per share for the current financial year, with EPS estimates ranging from $1.05 to $1.14. For the next financial year, analysts anticipate that the firm will report earnings of $1.28 per share, with EPS estimates ranging from $1.04 to $1.40. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Horizon Pharma PLC.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma PLC had a negative net margin of 45.28% and a positive return on equity of 20.22%. The company’s revenue for the quarter was up 30.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.70 earnings per share.

HZNP has been the topic of a number of recent analyst reports. Piper Jaffray Companies set a $17.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Tuesday, July 25th. BMO Capital Markets restated a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a research report on Friday, July 28th. Cantor Fitzgerald set a $13.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Monday, July 31st. BidaskClub lowered shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, UBS AG set a $16.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company. Horizon Pharma PLC has an average rating of “Buy” and an average price target of $18.42.

Horizon Pharma PLC (HZNP) traded up $0.35 during trading hours on Monday, reaching $13.48. 2,080,182 shares of the company’s stock were exchanged, compared to its average volume of 3,503,477. The firm has a market capitalization of $2,160.00, a price-to-earnings ratio of 9.47, a PEG ratio of 1.11 and a beta of 1.32. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. raised its stake in shares of Horizon Pharma PLC by 2.6% during the first quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 420 shares during the last quarter. Sheaff Brock Investment Advisors LLC raised its stake in shares of Horizon Pharma PLC by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 500 shares during the last quarter. Amalgamated Bank raised its stake in shares of Horizon Pharma PLC by 4.8% during the second quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 943 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Horizon Pharma PLC by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 1,378 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Horizon Pharma PLC by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock valued at $1,495,000 after purchasing an additional 1,379 shares in the last quarter. 83.80% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/analysts-expect-horizon-pharma-plc-hznp-will-post-earnings-of-0-22-per-share/1708272.html.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma PLC (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.